Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2016

Open Access 01-12-2016 | Research

RETRACTED ARTICLE: TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells

Authors: Xiaolin Wang, Weiping Shi, Hongcan Shi, Shichun Lu, Kang Wang, Chao Sun, Jiansheng He, Weiguo Jin, Xiaoxia Lv, Hui Zou, Yusheng Shu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2016

Login to get access

Abstract

Background

Tripartite Motif Containing 11 (TRIM11), a member of TRIM proteins, is overexpressed in high-grade gliomas and plays an oncogenic function in glioma biology. However, little is known about the role of TRIM11 in lung cancer.

Methods

We analyzed TRIM11 mRNA expression in lung cancer tissues and adjacent non-neoplastic tissues by real-time PCR. We then explored the function of TRIM11 in lung cancer cells by small interfering RNA-mediated downregulation of this protein followed by analyses of cell proliferation, migration and invasion.

Results

TRIM11 was highly expressed in lung cancer tissues and lung cancer cell lines. The higher expression of TRIM11 was correlated with the poorer prognosis of patients. Suppressing of TRIM11 expression in lung cancer cells with higher expression of TRIM11 (A549 and NCI-H446 cells) significantly reduced cell growth, motility and invasiveness. We further demonstrated that knockdown of TRIM11 affected the expression of cell proliferation-related proteins (Cyclin D1 and PCNA), and epithelial-mesenchymal transformation-related proteins (VEGF, MMP-2, MMP-9, Twist1, Snail and E-cadherin). The activity of ERK and PI3K/AKT was also suppressed in TRIM11 knocked down cells. Further experiments in lung cells with lower expression of TRIM11 (NCI-H460 and NCI-H1975 cells) with AKT inhibitor suggested that TRIM11 may promote cell motility and invasiveness through AKT pathway.

Conclusions

Our results indicate that TRIM11 acts as an oncogene in lung cancer through promoting cell growth, migration and invasion. Our findings may have important implication for the detection and treatment of lung cancer.
Appendix
Available only for authorised users
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
2.
Koudelakova V, Kneblova M, Trojanec R, Drabek J, Hajduch M. Non-small cell lung cancer--genetic predictors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157:125–36.CrossRefPubMed
3.
Longo-Sorbello GS, Chen B, Budak-Alpdogan T, Bertino JR. Role of pemetrexed in non-small cell lung cancer. Cancer Invest. 2007;25:59–66.CrossRefPubMed
4.
Zhou N, Wang H, Liu H, Xue H, Lin F, Meng X, et al. Mta1-upregulated epcam is associated with metastatic behaviors and poor prognosis in lung cancer. J Exp Clin Cancer Res. 2015;34:157.CrossRefPubMedPubMedCentral
5.
Cai S, Ye Z, Wang X, Pan Y, Weng Y, Lao S, et al. Overexpression of p21-activated kinase 4 is associated with poor prognosis in non-small cell lung cancer and promotes migration and invasion. J Exp Clin Cancer Res. 2015;34:48.CrossRefPubMedPubMedCentral
6.
Liu M, Zhou K, Huang Y, Cao Y. The candidate oncogene (mcrs1) promotes the growth of human lung cancer cells via the mir-155-rb1 pathway. J Exp Clin Cancer Res. 2015;34:121.CrossRefPubMedPubMedCentral
7.
8.
Niikura T, Hashimoto Y, Tajima H, Ishizaka M, Yamagishi Y, Kawasumi M, et al. A tripartite motif protein trim11 binds and destabilizes humanin, a neuroprotective peptide against alzheimer’s disease-relevant insults. Eur J Neurosci. 2003;17:1150–8.CrossRefPubMed
9.
Ishikawa H, Tachikawa H, Miura Y, Takahashi N. Trim11 binds to and destabilizes a key component of the activator-mediated cofactor complex (arc105) through the ubiquitin-proteasome system. FEBS Lett. 2006;580:4784–92.CrossRefPubMed
10.
Tuoc TC, Stoykova A. Trim11 modulates the function of neurogenic transcription factor pax6 through ubiquitin-proteosome system. Genes Dev. 2008;22:1972–86.CrossRefPubMedPubMedCentral
11.
Hong SJ, Chae H, Lardaro T, Hong S, Kim KS. Trim11 increases expression of dopamine beta-hydroxylase gene by interacting with phox2b. Biochem Biophys Res Commun. 2008;368:650–5.CrossRefPubMedPubMedCentral
12.
Di K, Linskey ME, Bota DA. Trim11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth. Oncogene. 2013;32:5038–47.CrossRefPubMed
13.
Qin Y, Cui H, Zhang H. Overexpression of trim25 in lung cancer regulates tumor cell progression. Technol Cancer Res Treat. 2015;9(1):23-45.
14.
Khatamianfar V, Valiyeva F, Rennie PS, Lu WY, Yang BB, Bauman GS, Moussa M, Xuan JW. Trim59, a novel multiple cancer biomarker for immunohistochemical detection of tumorigenesis. BMJ Open. 2012;2(5):e001410.
15.
Huo X, Li S, Shi T, Suo A, Ruan Z, Yao Y. Tripartite motif 16 inhibits epithelial-mesenchymal transition and metastasis by down-regulating sonic hedgehog pathway in non-small cell lung cancer cells. Biochem Biophys Res Commun. 2015;460:1021–8.CrossRefPubMed
16.
Li H, Zhang Y, Zhang Y, Bai X, Peng Y, He P. Trim31 is downregulated in non-small cell lung cancer and serves as a potential tumor suppressor. Tumour Biol. 2014;35:5747–52.CrossRefPubMed
17.
Zhang YH, Wang Y, Yusufali AH, Ashby F, Zhang D, Yin ZF, et al. Cytotoxic genes from traditional chinese medicine inhibit tumor growth both in vitro and in vivo. J Integr Med. 2014;12:483–94.CrossRefPubMed
18.
Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.CrossRefPubMed
19.
Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009;1796:75–90.PubMed
20.
Roberts PJ, Der CJ. Targeting the raf-mek-erk mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–310.CrossRefPubMed
21.
Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase akt pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.CrossRefPubMed
22.
Yilmaz M, Christofori G. Emt, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15–33.CrossRefPubMed
23.
Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548–58.CrossRefPubMed
24.
Yang J, Weinberg RA. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818–29.CrossRefPubMed
25.
Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. Vegf and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med. 2011;17:347–62.CrossRefPubMed
26.
Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.CrossRefPubMed
27.
Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by erk, jnk, and p38 protein kinases. Science. 2002;298:1911–2.CrossRefPubMed
28.
29.
Fidler IJ. The pathogenesis of cancer metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–8.CrossRefPubMed
30.
Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated akt overexpression and loss of pten expression in non-small cell lung cancer confers poor prognosis. Lung Cancer. 2006;51:181–91.CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells
Authors
Xiaolin Wang
Weiping Shi
Hongcan Shi
Shichun Lu
Kang Wang
Chao Sun
Jiansheng He
Weiguo Jin
Xiaoxia Lv
Hui Zou
Yusheng Shu
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2016
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-016-0379-y

Other articles of this Issue 1/2016

Journal of Experimental & Clinical Cancer Research 1/2016 Go to the issue

Research

MicroRNA-19b-3p regulates nasopharyngeal carcinoma radiosensitivity by targeting TNFAIP3/NF-κB axis

Research

Reactivation of mutant p53 by capsaicin, the major constituent of peppers

Research

SYNJ2BP inhibits tumor growth and metastasis by activating DLL4 pathway in hepatocellular carcinoma

Research

MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression

Research

Prohibitin overexpression predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbladder cancer

Research

Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits